SunTrust analyst John Boris lowered his price target on Amarin after the company guided its FY19 revenue outlook well below consensus and offered more details timing of Vascepa sNDA filing. The analyst contends that the company needs to employ a larger sales force to "realize Vascepa full potential" beyond the 400 reps currently and also lowers his FY19 EPS view to (23c) from 18c to reflect Amarin's expectations of lower sales and higher SG&A costs. Longer term, Boris keeps his Buy rating on Amarin, noting that Vascepa could have a "significant commercial upside" if it can secure a label for reducing cardiovascular risk.

Amarin Corporation announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting. Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. company law, and if approved by the U.K. High Court, commence the share repurchase program by the end of the second quarter of 2024. As part of the Annual General Meeting, shareholders also approved the following resolutions: Re-elected Mr. Patrick Holt, Mr. Louis Sterling III and Ms. Patrice Bonfiglio as directors of the Company; Approved the compensation of the Company's "named executive officers" as described in full in the "Executive Compensation Discussion and Analysis" section of the Company's definitive proxy statement; Approved the appointment of Ernst & Young LLP as auditors of the Company until the conclusion of the next general meeting; Approved the proposed amendment to the Company's 2020 Stock Incentive Plan; Authorized and approved the amended and restated articles of association to require all directors to retire and seek re-election at each annual general meeting of the Company.